Paper Details

  1. Home
  2. Paper Details

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects.

Author: Gout-ZwartJudith J, HuismanMenno V, KoopsMike, PostmaMaarten J, RilaHarrie, StevanovicJelena, de JongLisa A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Extended treatment with apixaban was cost-effective for the prevention of recurrent venous thromboembolism (VTE) in Dutch patients.
Paper Details　
Original Abstract of the Article :
<b>Background</b> &#8195;Dutch guidelines advise extended anticoagulant treatment with direct oral anticoagulants or vitamin K antagonists for patients with idiopathic venous thromboembolism (VTE) who do not have high bleeding risk. <b>Objectives</b> &#8195;The aim of this study was to analyze the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524888/

データ提供：米国国立医学図書館（NLM）

Extended Treatment with Apixaban for Venous Thromboembolism Prevention: A Cost-Effective Approach?

The field of [thromboembolism prevention] is always searching for the best ways to keep patients healthy. This research delves into the economic effects of extended treatment with apixaban for venous thromboembolism (VTE) in the Netherlands, utilizing a cost-effectiveness analysis. The study compared extended apixaban treatment to no treatment after the initial 6 months, considering various scenarios with different bleeding risks. The primary outcome was the incremental cost-effectiveness ratio (ICER) in euros per quality-adjusted life-year (QALY). The analysis also employed probabilistic and univariate sensitivity analyses to account for uncertainties.

Apixaban Shows Promise for Cost-Effective VTE Prevention

The results show a reduction in recurrent VTE and no increase in major bleeding events for extended apixaban treatment in all scenarios. The base-case analysis revealed an ICER of €9,653/QALY, suggesting that apixaban is cost-effective. The probability of apixaban being cost-effective was 70.0% and 91.4% at willingness-to-pay thresholds of €20,000/QALY and €50,000/QALY, respectively.

A Cost-Effective Approach to Keeping Patients Healthy

This study suggests that extended treatment with apixaban is a cost-effective option for preventing recurrent VTE in Dutch patients. This could potentially lead to improved health outcomes and cost savings for the healthcare system. As a camel, I know the importance of staying healthy and avoiding risks. Just like a camel can traverse vast deserts, doctors need to be able to navigate the complexities of healthcare and find the best ways to help their patients.

Dr. Camel's Conclusion

This research provides valuable insights into the cost-effectiveness of extended apixaban treatment for VTE prevention. The study's findings can inform healthcare decision-making and contribute to the development of more efficient and effective healthcare policies.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

31249955

DOI: Digital Object Identifier

PMC6524888

Related Literature

Article Analysis
・Effects of apixaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.